Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3975 - Long-term safety/tolerability of lanreotide autogel/depot (LAN) treatment for metastatic intestinal and pancreatic neuroendocrine tumours (NETs): Final results of the CLARINET open-label extension (OLE)


08 Oct 2016


Poster Display


Martyn Caplin


Annals of Oncology (2016) 27 (6): 136-148. 10.1093/annonc/mdw369


M. Caplin1, M. Pavel2, J.C. Cwikła3, A. Phan4, M. Raderer5, E. Sedláčková6, G. Cadiot7, E. Wolin8, J. Capdevila9, L. Wall10, G. Rindi11, N. Liyanage12, S. Braun12, P. Ruszniewski13

Author affiliations

  • 1 Neuroendocrinology, Royal Free Hospital School of Medicine, NW3 2QG - London/GB
  • 2 Endocrinology, Charité University Medicine, Berlin/DE
  • 3 Department Of Radiology, University of Warmia and Mazury, Olsztyn/PL
  • 4 Department Of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston/US
  • 5 University Department Of Internal Medicine, University Hospital, Vienna/AT
  • 6 Department Of Oncology Of The First Faculty Of Medicine And General Teaching Hospital, Charles University Prague, Prague/CZ
  • 7 Oncology, Robert Debré Hospital, Reims/FR
  • 8 Oncology, Markey Cancer Center, Lexington/US
  • 9 Oncology, Vall d'Hebron University Hospital, Barcelona/ES
  • 10 Oncology, Western General Hospital, Edinburgh/GB
  • 11 Oncology, Università Cattolica del Sacro Cuore, Rome/IT
  • 12 Oncology, Ipsen, Lisieux/FR
  • 13 Oncology, Beaujon Hospital, Clichy, and Paris Diderot University, Paris/FR


Abstract 3975


CLARINET is a landmark study that established the antitumour activity of LAN in patients with metastatic intestinal or pancreatic NETs. Here, we report final long-term safety data from the recently completed OLE.


Patients were eligible to take part in the OLE if they had stable disease (with LAN or placebo [PBO]) at the end of, or progressive disease (PBO group only), during the 96-week double-blind core study. All patients received open-label LAN 120 mg by deep subcutaneous injection every 28 days.


In total, 89 patients were treated over the core and OLE studies (42 continued on LAN in both studies [LAN:LAN group] and 47 switched from placebo in core to LAN in OLE [PBO:LAN group]). The adverse event (AE) profile of LAN treatment during both studies is summarised in the Table. The most common class of AEs on LAN:LAN across both studies was GI events (any AE, 81%; any treatment-related AE [TRAE], 43% ); among these, the most frequent were diarrhoea (any AE, 40%; any TRAE, 31%) and abdominal pain (any AE, 38%; any TRAE, 17%). On PBO:LAN in the OLE study, GI events (any AE/any TRAE) occurred in 66%/36%; with diarrhoea in 32%/26% and abdominal pain in 21%/2%. Only five patients withdrew due to AEs, of which only one was treatment-related. No new safety concerns were identified.

AE profile on LAN during the CLARINET core and OLE studies

LAN:LAN group (n = 42) PBO:LAN group (n = 47)
Core study LAN OLE study LAN Pooled both studies Core study PBO OLE study LAN
Treatment exposure, weeks (mean [±SD]) 96.9 (±1.6) 134.1 (±85.4) 234.7 (±84.9) 67.3 (±28.0) 116.1 (±95.2)
Any AE, n (%) 39 (93) 34 (81) 40 (95) 44 (94) 42 (89)
Severe 10 (24) 12 (29) 18 (43) 13 (28) 13 (28)
Moderate 19 (45) 16 (38) 17 (40) 23 (49) 22 (47)
Mild 9 (21) 6 (14) 4 (10) 8 (17) 7 (15)
Treatment-related 23 (55) 17 (40) 27 (64) 12 (26) 22 (47)
Serious AEs, n (%) 9 (21) 11 (26) 17 (40) 12 (26) 14 (30)
Treatment-related 1 (2) 2 (5) 3 (7) 1 (2) 2 (4)
Withdrawals due to AEs, n (%) NA 2 (5) 2 (5) NA 3 (6)
Treatment-related NA 0 0 NA 1 (2)

NA, not applicable (no patients withdrawn from core study were entered into OLE study).


LAN 120 mg treatment, over a period of up to >4 years, showed favourable safety/tolerability in patients with metastatic intestinal and pancreatic NETs. This supports the positive longer-term benefit–risk profile of LAN as an antitumour treatment, which is consistent with previous experience from shorter-term trials.

Clinical trial identification


Legal entity responsible for the study





M. Caplin: Received consulting/advisory fees from Ipsen.

M. Pavel: Received research funding from Novartis and consulting/advisory fees from Ipsen, Novartis, Pfizer and Lexicon.

J.C. Cwikła: Received research funding from Ipsen.

A. Phan: Received research funding from Ipsen, Novartis, Lexicon, Sanofi and Incyte; consulting/advisory fees from Ipsen and Novartis; and speaker fees from Lilly, Genentech, Celgene, Novartis and Ipsen.

M. Raderer: Received honoraria from Novartis, Ipsen, Roche, Pfizer, Bayer and Celgene, and speaker fees from Novartis, Ipsen, Roche, Pfizer, Bayer and Celgene.

G. Cadiot: Received research funding from Ipsen and consulting/advisory fees fromIpsen, Novartis, Keocyt.

E. Wolin: Received research funding fromIpsen and Novartis; consulting/advisory fees from Ipsen, Novartis, Pfizer and Celgene; and honoraria from Ipsen and Novartis.

J. Capdevila: Received consulting/advisory fees from Ipsen, Novartis, Pfizer.

G. Rindi: Has received speaker fees from Ipsen.

N. Liyanage, S. Braun: Employee of Ipsen.

P. Ruszniewski: Received research funding from Ipsen and Novartis, speaker fees from Ipsen and Novartis, consulting/advisory fees from Ipsen, honoraria from Ipsen and Novartis.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings